<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28667666</article-id>
<article-id pub-id-type="pmc">5595756</article-id>
<article-id pub-id-type="doi">10.1111/bph.13938</article-id>
<article-id pub-id-type="publisher-id">BPH13938</article-id>
<article-id pub-id-type="other">2017-BJP-0311-RCT-G.R2</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Themed Section: Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies</article-title>
<alt-title alt-title-type="right-running-head">Molecular basis of schizophrenia and pro‐cognitive therapeutics</alt-title>
<alt-title alt-title-type="left-running-head">C M P O'Tuathaigh et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="bph13938-cr-0001">
<name>
<surname>O'Tuathaigh</surname>
<given-names>Colm M P</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1365-1606</contrib-id>
<address>
<email>c.otuathaigh@ucc.ie</email>
</address>
<xref ref-type="aff" rid="bph13938-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13938-cr-0002">
<name>
<surname>Moran</surname>
<given-names>Paula M</given-names>
</name>
<xref ref-type="aff" rid="bph13938-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13938-cr-0003">
<name>
<surname>Zhen</surname>
<given-names>Xuechu C</given-names>
</name>
<xref ref-type="aff" rid="bph13938-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13938-cr-0004">
<name>
<surname>Waddington</surname>
<given-names>John L</given-names>
</name>
<xref ref-type="aff" rid="bph13938-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="bph13938-aff-0004">
<sup>4</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph13938-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">School of Medicine</named-content>
<institution>University College Cork, Brookfield Health Sciences Complex</institution>
<named-content content-type="city">Cork</named-content>
<country country="IE">Ireland</country>
</aff>
<aff id="bph13938-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">School of Psychology</named-content>
<institution>University of Nottingham</institution>
<named-content content-type="city">Nottingham</named-content>
<country country="GB">UK</country>
</aff>
<aff id="bph13938-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Jiangsu Key Laboratory of Translational Research &amp; Therapy for Neuropsychiatric Disorders and Department of Pharmacology, College of Pharmaceutical Sciences</named-content>
<institution>Soochow University</institution>
<named-content content-type="city">Suzhou</named-content>
<country country="CN">China</country>
</aff>
<aff id="bph13938-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Molecular and Cellular Therapeutics</named-content>
<institution>Royal College of Surgeons in Ireland</institution>
<named-content content-type="city">Dublin 2</named-content>
<country country="IE">Ireland</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence Colm O'Tuathaigh, School of Medicine, University College Cork, Brookfield Health Sciences Complex, College Road, Cork, Ireland.<break></break>
E‐mail: <email>c.otuathaigh@ucc.ie</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2017</year>
</pub-date>
<volume>174</volume>
<issue>19</issue>
<issue-id pub-id-type="doi">10.1111/bph.v174.19</issue-id>
<issue-title content-type="special-issue-title">Themed Section: Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? Guest Editors: Sarah J Bailey, Joanna C Neill and Paula M Moran</issue-title>
<fpage>3173</fpage>
<lpage>3190</lpage>
<history>
<date date-type="received">
<day>03</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>07</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>6</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-174-3173.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>The presence and severity of cognitive symptoms, including working memory, executive dysfunction and attentional impairment, contributes materially to functional impairment in schizophrenia. Cognitive symptoms have proved to be resistant to both first‐ and second‐generation antipsychotic drugs. Efforts to develop a consensus set of cognitive domains that are both disrupted in schizophrenia and are amenable to cross‐species validation (e.g. the National Institute of Mental Health Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia and Research Domain Criteria initiatives) are an important step towards standardization of outcome measures that can be used in preclinical testing of new drugs. While causative genetic mutations have not been identified, new technologies have identified novel genes as well as hitherto candidate genes previously implicated in the pathophysiology of schizophrenia and/or mechanisms of antipsychotic efficacy. This review comprises a selective summary of these developments, particularly phenotypic data arising from preclinical genetic models for cognitive dysfunction in schizophrenia, with the aim of indicating potential new directions for pro‐cognitive therapeutics.</p>
<sec id="bph13938-sec-1001">
<title>Linked Articles</title>
<p>This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc">http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc</ext-link>
</p>
</sec>
</abstract>
<counts>
<fig-count count="0"></fig-count>
<table-count count="2"></table-count>
<page-count count="18"></page-count>
<word-count count="8021"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph13938</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>October 2017</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.9 mode:remove_FC converted:12.09.2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph13938-cit-0000" publication-type="journal">
<string-name>
<surname>O'Tuathaigh</surname>, <given-names>C. M. P.</given-names>
</string-name>, <string-name>
<surname>Moran</surname>, <given-names>P. M.</given-names>
</string-name>, <string-name>
<surname>Zhen</surname>, <given-names>X. C.</given-names>
</string-name>, and <string-name>
<surname>Waddington</surname>, <given-names>J. L.</given-names>
</string-name> (<year>2017</year>) <article-title>Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies</article-title>. <source/>British Journal of Pharmacology, <volume>174</volume>: <fpage>3173</fpage>–<lpage>3190</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/bph.13938">10.1111/bph.13938</ext-link>.</mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>